User:Letícia Oliveira Rojas Cruz/Sandbox 1
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
- | ==Angiotensin-converting enzyme 2 (ACE2)== | + | ==Angiotensin-converting enzyme 2 (ACE2)-(PDB 1R42)== |
<StructureSection load='6m17' size='425' side='right' caption='PDB 6m17' scene='10/1083732/Ace2_completa/3'> | <StructureSection load='6m17' size='425' side='right' caption='PDB 6m17' scene='10/1083732/Ace2_completa/3'> | ||
- | <scene name='10/1083732/Ace2_completa/3'>Angiotensin-converting enzyme 2 (ACE2)</scene> is an important protein expressed in several human tissues, such as the heart and kidneys. It plays a key role in the Renin-Angiotensin System - " | + | <scene name='10/1083732/Ace2_completa/3'>Angiotensin-converting enzyme 2 (ACE2)</scene> is an important protein expressed in several human tissues, such as the heart and kidneys. It plays a key role in the Renin-Angiotensin-Aldosterone System - "RAAS" - by catalyzing the conversion of angiotensin II (Ang II), promoting blood pressure regulation. |
Another function of ACE2 is related to SARS-CoV-2 infection, the virus responsible for the COVID-19 pandemic. In this context, ACE2 serves as the entry receptor for the virus. <ref>PMID:33389262</ref> | Another function of ACE2 is related to SARS-CoV-2 infection, the virus responsible for the COVID-19 pandemic. In this context, ACE2 serves as the entry receptor for the virus. <ref>PMID:33389262</ref> | ||
Line 22: | Line 22: | ||
<scene name='10/1083732/Ace2_completa/3'>ACE2</scene> is a transmembrane glycoprotein that has an extracellular catalytic domain. It is classified as a hydrolase, more specifically a carboxypeptidase-type peptidase, responsible for the cleavage of peptide bonds at the C-terminal site. <ref>PMID:17897633</ref> | <scene name='10/1083732/Ace2_completa/3'>ACE2</scene> is a transmembrane glycoprotein that has an extracellular catalytic domain. It is classified as a hydrolase, more specifically a carboxypeptidase-type peptidase, responsible for the cleavage of peptide bonds at the C-terminal site. <ref>PMID:17897633</ref> | ||
The ACE2 acts to cleave a single C-terminal residue of some substrates. One of those substrates is Angiotensin II (Ang II), which is degrated into Angiotensin-(1-7); to a lesser extent, Angiotensin I (Ang I) is also a substrate, turning in into Angiotensin-(1-9). | The ACE2 acts to cleave a single C-terminal residue of some substrates. One of those substrates is Angiotensin II (Ang II), which is degrated into Angiotensin-(1-7); to a lesser extent, Angiotensin I (Ang I) is also a substrate, turning in into Angiotensin-(1-9). | ||
- | The Renin-Angiotensin System - " | + | The Renin-Angiotensin-Aldosterone System - "RAAS" -, in which ACE2 acts, is an important signaling pathway responsible for vascular homeostasis. |
- | In general, Ang II, generated by the action of ACE on Ang I, and this one by the action of Renin on Angiotensinogen, acts on AT1 and AT2 receptors. Its main action is vasoconstriction (by AT1 receptor), increasing blood pressure. On the other hand, Angiotensin (1-7), generated from Ang II by ACE2, has the opposite function, leading to a decline in blood pressure through vasodilation and release of Nitric Oxide (NO) through its action on the MAS oncogene receptor, antagonizing the actions of Ang II. <ref>PMID:19461648</ref> | + | In general, Ang II, generated by the action of ACE on Ang I, and this one by the action of Renin on Angiotensinogen, acts on AT1 and AT2 receptors. Its main action is vasoconstriction (by AT1 receptor), increasing blood pressure. On the other hand, Angiotensin (1-7), generated from Ang II by ACE2, has the opposite function, leading to a decline in blood pressure through vasodilation and release of Nitric Oxide (NO) through its action on the MAS oncogene receptor, antagonizing the actions of Ang II. <ref>PMID:19461648</ref> |
== Pathological Relevance == | == Pathological Relevance == |
Revision as of 21:56, 9 July 2025
Angiotensin-converting enzyme 2 (ACE2)-(PDB 1R42)
|
References
- ↑ Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Dis. 2021 May;40(5):905-919. PMID:33389262 doi:10.1007/s10096-020-04138-6
- ↑ Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system. Biochem Pharmacol. 2008 Feb 15;75(4):781-6. PMID:17897633 doi:10.1016/j.bcp.2007.08.012
- ↑ Iwai M, Horiuchi M. Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1-7)-Mas receptor axis. Hypertens Res. 2009 Jul;32(7):533-6. PMID:19461648 doi:10.1038/hr.2009.74
- ↑ Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Muller MA, Drosten C, Pohlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020, Mar 5. PMID:32142651 doi:http://dx.doi.org/10.1016/j.cell.2020.02.052
- ↑ Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020 Mar 4. pii: science.abb2762. doi: 10.1126/science.abb2762. PMID:32132184 doi:http://dx.doi.org/10.1126/science.abb2762
OUDIT, G. Y. et al. Angiotensin-converting enzyme 2—at the heart of the COVID-19 pandemic. Cell, v. 186, n. 5, p. 906–922, mar. 2023.